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Circulating biochemical markers of bone remodeling in uremic of bone matrix constituents, such as collagen and ground
patients. Chronic renal failure is often associated with bone substances. Bone resorption depends on osteoclasts,
disorders, including secondary hyperparathyroidism, alumi- which are giant multinucleated cells that are usuallynum-related low-turnover bone disease, osteomalacia, ady-
found in contact with calcified bone surfaces and withinnamic osteopathy, osteoporosis, and skeletal b2-microglobulin
the lacuna resulting from its own resorptive activity. Theamyloid deposits. In spite of the enormous progress made dur-
ing the last few years in the search of noninvasive methods to combination of these two processes is defined as bone
assess bone metabolism, the distinction between high- and low- remodeling [2]. Despite the fact that they occur along
turnover bone diseases in these patients still frequently requires the bone surface at random and that bone formationinvasive and/or costly procedures such as bone biopsy after
only takes place where resorption of old bone has alreadydouble tetracycline labeling, scintigraphic-scan studies, com-
puted tomography, and densitometry. This review is focused occurred, both processes appear to be very well coupled
on the diagnostic value of several new serum markers of bone in normal conditions, to the point that the equilibrium
metabolism, including bone-specific alkaline phosphatase (bAP), between bone resorption and bone formation will deter-
procollagen type I carboxy-terminal extension peptide (PICP),
mine the gain, loss, or balance of total bone mass [1, 2].procollagen type I cross-linked carboxy-terminal telopeptide
Most of the metabolic bone diseases are characterized(ICTP), pyridinoline (PYD), osteocalcin, and tartrate-resistant
acid phosphatase (TRAP) in patients with chronic renal failure. by an alteration in the bone resorption/formation bal-
Most of the observations made by several groups converge to ance. In the course of chronic renal failure, before kidney
the conclusion that serum bAP is the most sensitive and specific graft, situations are often found in which there is a dif-marker to evaluate the degree of bone remodeling in uremic
fuse or local increase of bone resorption such as secondarypatients. Nonetheless, PYD and osteocalcin, in spite of their
hyperparathyroidism, osteoporosis, mixed bone diseases,retention and accumulation in the serum of renal insufficient
patients, are also excellent markers of bone turnover. The and b2-microglobulin osteoarthropathy [3–6]. There are
future generalized use of these markers, individually or in com- also situations in which there is a rather normal or de-
bination with other methods, will undoubtedly improve the
creased bone remodeling such as aluminum-related lowdiagnosis and the treatment of the complex renal osteodys-
bone turnover, osteomalacia, adynamic osteopathy, andtrophy.
extraskeletal calcifications [3–13]. After renal trans-
plantation, in addition to the persistence of one or several
of the previously mentioned disorders, three histologi-Bone is a specialized connective tissue composed of
cally and less characterized entities can also be observed:cells and an extracellular matrix that has the unique
painful legs syndrome, avascular bone necrosis, and im-ability to become calcified, thereby forming, in conjunc-
munosuppression-related bone disease (Table 1) [14].tion with cartilage, the skeletal system [1]. Its metabolism
is characterized by two opposed processes: formation To date, the only method of making a clear-cut distinc-
and resorption. The formation depends on osteoblasts, tion between high, normal, and/or low bone remodeling
which are bone lining cells responsible for the production in these patients relies on the static and dynamic histolog-
ical analyses of the iliac bone biopsy after double tetracy-
cline labeling [3, 12]. This histological diagnosis can be
Key words: chronic renal failure, hemodialysis, renal osteodystrophy,
complemented by clinical and radiographic signs, tomo-bone alkaline phosphatase, osteocalcin, collagen crosslinks.
densitometry, densitometry, scintigraphy, and the results
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Table 2. Circulating biochemical markers of bone remodelingTable 1. Osteo-articular complications of chronic renal failure
Before kidney transplantation Bone formation
Total alkaline phosphatases (tAP)Osteomalacia (vitamin D deficiency)
Secondary hyperparathyroidism (HPTH-II) Bone-specific alkaline phosphatase (bAP)
OsteocalcinAluminum-related osteopathy
Mixed osteodystrophy (aluminum and HPTH-II) Procollagen type-I carboxy-terminal extension peptide (PIPC)
Insulin-like growth factor-I (IGF-I)Osteoporosis
Adynamic osteopathy Bone resorption
Tartrate-resistant acid phosphatase (TRAP)Extra-skeletal calculations
b2-microglobulin osteo-arthropathy Pyridinoline (PYD)
Deoxypyridinoline (DPD)After kidney transplantation
Painful legs syndrome Procollagen type-I cross-linked carboxy-terminal telopeptide
(ICTP)Avascular bone necrosis
Immunosuppression-related bone disease b2-microglobulin (b2m)
Bone sialoprotein
Advanced glycatation end-products (AGEs)
Advanced oxidation protein products (AOPP)
Cytokines (IL-1, IL-6, IL-11, TNFa, TGFb, IFNg,)
Growth factors (MCS-F, GMCS-F)experienced teams and appropriate laboratory facilities.
Other potential markersOther workers have become reluctant to perform bone Osteopontin
biopsies, claiming that the procedure is particularly pain- Osteonectin
Fibronectinful and often refused by many patients. However, it has
Bone morphometric proteins (BMPs) and their solublebeen proved that such a procedure is safe and free from receptors
major complications, with the incidence of complications Prostaglandin E2
Plasminogene activator factor (PAF)being lower than 0.7%, without death or permanent dis-
Inhibitor of the plasminogene activator factor (PAF-I)abilities [20, 21]. Moreover, many of the studies men- Cathepsins
tioned earlier in this article are also invasive or too ex- Integrins
Nitric oxidepensive to be performed routinely. Thus, considerable
efforts have been devoted to the development of reliable
noninvasive methods to assess bone metabolism in ure-
mic patients.
trate-resistant acid phosphatase (TRAP) and/or some ofThus, for a long time, the biochemical diagnosis or
the multiple products resulting from the degradation ofthe presumption of the histological type of renal osteo-
type I collagen. Other circulating molecules might alsodystrophy has been essentially based on the plasma intact
prove to be of potential interest in evaluating bone turn-parathyroid hormone (iPTH) concentration because of
over, namely, bone sialoprotein, b2-microglobulin, ca-its relative good correlation with bone histomorphome-
thepsins, nitric oxide, advanced oxidation protein prod-tric parameters [22–26]. However, it is now obvious that
ucts (AOPPs), advanced glycation end products (AGEs),the measurement of a single parameter such as plasma
cytokines as interleukins (IL-1, IL-6, and IL-11), solubleiPTH does not provide sufficient information to make
IL-6 receptor, tumor necrosis factor-a (TNF-a), trans-a final diagnosis. First, the plasma iPTH concentration
forming growth factor-b (TGF-b), bone morphometricbasically reflects the degree of activity of parathyroid
glands. Second, given that the uremic state is often asso- proteins (BMBPs) and their soluble receptors, growth
ciated with a resistance of bone cells to the actions of factors such as insulin growth factor-I (IGF-I), macro-
PTH, the relationship between plasma iPTH levels and phage colony-stimulating factor (MCS-F), and granulo-
bone formation rate (BFR) is not always maintained cyte-macrophage colony stimulating factor (GMCF-F;
[27–29]. Since 1992, this has led to the assumption that Table 2) [33–45].
plasma iPTH values should be maintained between 120 In this review, we analyze several of the most recent
and 400 pg/ml in order to preserve an appropriate level serum markers of bone remodeling, including bAP,
of bone remodeling [30], whereas usually normal values PICP, procollagen type I cross-linked carboxy-terminal
are below 65 pg/ml. Third, plasma iPTH values obtained telopeptide (ICTP), pyridinoline (PYD), deoxypyridino-
with current radioimmunologic methods might be over- line (DPD), OC, and TRAP, and evaluate their use-
estimating the real iPTH concentration by 1.0- to 1.5- fulness as noninvasive tests for the assessment of the
fold [31, 32]. degree of bone remodeling in the setting of renal insuffi-
Fortunately, it has now become possible to estimate ciency.
the degree of BFR by measuring either plasma levels of
bone-specific alkaline phosphatase (bAP), osteocalcin
BONE-SPECIFIC ALKALINE PHOSPHATASE(OC), or procollagen type I carboxy-terminal extension
Six alkaline phosphatase isoenzymes have been identi-peptide (PICP). Similarly, the intensity of bone resorp-
tion can be evaluated by measuring serum levels of tar- fied so far: hepatic, intestinal, skeletal, renal, placental,
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Table 3. Bone markers in hemodialyzed patientsand tumoral [46–49]. Such diversity is partly due to the
existence of at least four human genes, three of them on Normal/low
High turnover turnoverchromosome 2q34-37 and the other one on chromosome
bone disease bone disease1p36.1-34. One single gene codes for the tissue nonspe-
N N Pcific group of alkaline phosphatase (AP) that consists of
Intact PTH pg/ml 8316707 26 1426150 9 0.007liver, bone, and kidney isoforms, and these isoenzymes
tAP IU/liter 2826224 27 171678 10 NSdiffer only by post-transcriptional glycosylation [50]. The
bAP ng/ml 69.8663.9 27 10.764.4 9 0.009
bone-specific isoenzyme or bAP has a molecular weight Osteocalcin ng/ml 5556423 22 1986261 9 0.02
ICTP mg/liter 33.2616.6 11 40.165.9 6 NSof 80 kDa. It is neither dialyzable nor filtrable by the
PICP mg/liter 2546118 24 200633.0 9 NSkidneys; therefore, its plasma concentration is not modi-
Pyridinoline nm 1096108 27 34.1612.8 10 0.04
fied by variations in the renal function. Bone AP is exclu-
Abbreviations are: PICP, procollagen type-I carboxy-terminal extension pep-
sively produced by osteoblasts, first in an intracellular tide; ICTP, procollagen type-I cross-linked telopeptide; tAP, total alkaline phos-
phatases; bAP, bone-specific alkaline phosphatase [22].tetrameric form. Then it is anchored to the outer surface
of the cellular membrane to inositol phosphate by a
glycan ester [48]. In vitro studies indicate that bAP activ-
ity is released from the osteoblastic surface in either of
zyme-linked immunosorbent assay (ELISA) from Metratwo forms: an anchorless, soluble (hydrophylic) form
Biosystems, Inc. (Palo Alto, CA, USA), which measuresand an anchor-intact, insoluble (hydrophobic) form [51].
the activity, correlate well with the values obtained byMost of the bAP that appears in human serum is essen-
separation methods such as Isopalt from Beckman (Palotially in the anchorless or soluble form. Its plasma con-
Alto, CA, USA) [65]. It has been suggested, however,centration depends on the rate of release from osteo-
that the electrophoretic method is more sensitive thanblasts and the rate of hepatic degradation [52].
the other methods when measuring low concentrationsBone AP is a robust molecule because most of its
of bAP [65, 66].activity is still found after 72 hours at 48C, after several
As expected, using these new methods, recent obser-years stocked at 2 208C, and after several cycles of freez-
vations have shown that plasma bAP is more sensitiveing and thawing. The physiological role of bAP is yet to
than total alkaline phosphatases (tAP), OC, and os-be fully understood. However, bAP seems to be essential
teonectin in the evaluation of bone remodeling in chronicfor the process of mineralization and bone formation.
renal patients [27, 29, 67–71]. Furthermore, because theIt catalyzes the hydrolysis of phosphate ester, thereby
monoclonal antibody against bAP exhibits a low cross-enhancing the mineralization by hydrolysis of pyrophos-
reactivity with other alkaline phosphatases, it has be-phate, which is an important inhibitor of mineralization,
come possible to differentiate the elevation of tAP seenand by providing a high phosphate concentration at the
in liver diseases from that caused by osteopathies [56,osteoblastic surface [46, 53]. Moreover, molecular exper-
65, 72–77].iments showed that the transfection of its cDNA confers
During life, there are two age-dependent physiologicalthe capacity of mineralization to cells normally lacking
peaks of plasma bAP, one during infancy and the otherthe alkaline phosphatase gene [50]. Likewise, alkaline
during puberty. Both peaks are disturbed in pediatricphosphatases may be important in the vitamin B metabo-
uremic patients in accordance with their altered longitu-lism. Transgenic mice in which the AP gene has been
dinal growth [78]. Nonetheless, in such children, plasmaknocked out by homologous recombination die of sei-
bAP correlated with iPTH and not with tAP and showedzures and vitamin B6 deficiency [54].
a better correlation with height velocity than tAP. PlasmaDifferent methods have been employed in order to
bAP correlates also with bone trabecular density, themeasure plasma AP isoforms, such as heat denaturation,
metabolically most active part of bone, pointing to itschemical activators or inhibitors of specific AP isoen-
significance as a marker of bone formation [77].zymes, wheat germ lectin or concanavalin A precipita-
In adult hemodialysis patients, values of plasma bAPtion, eventually followed by separation by agarose gel
higher than 20 ng/ml are constantly associated eitherelectrophoresis or by high-performance affinity chroma-
with biological and histological signs of secondary hyper-tography [55–59]. However, these methods are expen-
parathyroidism or with high bone turnover (Table 3)sive, laborious, time consuming, and of insufficient sensi-
[27]. In addition, plasma bAP correlates well with iPTH.tivity to be easily and reliably applied in clinical practice.
Such correlation is better than that of tAP with iPTHFortunately, specific monoclonal antibodies against bAP
(Fig. 1). Plasma bAP also correlated better than iPTHhave been successfully developed and used in radioim-
and tAP with most bone histomorphometric parameters,munological and immunoenzymatic assays [60–64]. The
including osteoclast and osteoblast surfaces [29]. Accord-values obtained using immunological assays such as Os-
ingly, when based on these bone parameters, the sensitiv-taset, IRMA from Hybritech (San Diego, CA, USA),
which measures the mass of bAP, and Alkaphaset, en- ity and specificity of a bAP of more than 20 ng/ml can
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Fig. 1. Relationship between plasma intact
parathyroid hormone (IPTH) and bone-spe-
cific alkaline phosphatase (bAP) in 142 adult
hemodialysis patients. Plasma IPTH was mea-
sured using a radioimmunometric assay for
intact human PTH 1-84 (Allegro Intact PTH;
Nichols Institute, San Juan Capistrano, CA,
USA). The range of normal values was be-
tween 10 and 70 pg/ml. Plasma bAP was mea-
sured using the radioimmunometric assay
Tandem-R (Ostase, Hybritech Europe S.A.,
Belgium). The mean 6 sd value obtained in
normal adult individuals was 11.8 6 4.3 ng/ml
(normal range 7.5 to 16.0 ng/ml). Dashed lines
indicate lower and upper limits for bAP levels
and upper limits for IPTH values (r 5 0.559;
N 5 142; P , 0.001).
reach 100% in the prediction of a high bone turnover patients have both bAP and iPTH within normal ranges.
In the zone of high values, there is a great variability.disease and a positive predictive value of 84% [29]. This
does not seem to be the case in the absence of bone For example, for comparable plasma bAP levels of 60
to 80 ng/ml, some patients have iPTH values of 500biopsy evidence. If the diagnosis of secondary hyperpara-
thyroidism is made on the basis of a iPTH of more than to 600 pg/ml and others 1000 to 1100 pg/ml, probably
reflecting different degrees of skeletal response to PTH.200 pg/ml and a bAP of more than 20 ng/ml, then the
sensitivity of bAP decreases to 56% and the specificity Forty-five to 50% of them have either low or high bAP
and iPTH. Twenty-five to 30% of the patients have in-to 92%, probably because a lot of patients have iPTH
values higher than 200 pg/ml without elevated bAP. Its creased plasma iPTH levels above 200 pg/ml and normal
bAP. Less frequently observed, 10 to 15% of the patientshigh specificity suggests, however, that a plasma bAP
higher than 20 ng/ml formally excludes the existence of have increased plasma bAP levels and normal iPTH
(Fig. 1) [27].a low or normal bone turnover [27, 29]. Similar results
have recently been reported by other workers [79]. In the cases of high plasma bAP associated with
plasma iPTH levels, which are either low or within theIn contrast, to give a plasma bAP value below which
there would be a great probability of having an adynamic limits considered as normal in such patients (less than
200 pg/ml) [30], several hypotheses have been presentedor low-turnover bone disease appears to be more diffi-
cult. The two bone biopsy-based studies reported so far to explain this phenomenon. First, the cut-off value of
20 ng/ml might be inadequate in the presence of a con-employed different and noncomparable methods of bAP
measurements [29, 66]. On the other hand, the low num- comitant increase of tAP. As reported earlier in this
article, the antibodies against bAP show a cross-reactiv-ber of adynamic bone disease (ABD) patients in one of
the studies did not allow us to obtain a sensitive plasma ity of only 16% with tAP. However, it has been demon-
strated that its radioimmunological measurement canbAP concentration predictive of ABD. However, from
these observations, it can be proposed that the diagnosis still be considered reliable if the elevation of tAP does
not exceed 2.6 times the upper normal limit [62]. Second,of ABD in hemodialysis patients should be suspected
when plasma iPTH levels are less than 150 pg/ml and as the liver, kidney, and bone AP isoenzymes are en-
coded by the same gene, there could be an extraskeletalthat bAP levels are lower than 7 ng/ml (Ostaset) or 27 U/
liter (Isopalt) [29, 66]. A recent study in 41 hemodialysis synthesis of bAP, either hepatic or renal. It is known
that liver cells of dialysis patients are often abnormallypatients who underwent a bone biopsy demonstrated
that a plasma bAP concentration lower than 12.9 ng/ml activated by virus contamination [49, 81, 82]. Third, the
production of skeletal bAP could be independent of thehad a sensitivity of 100%, a specificity of 94%, and a
positive predictive value of 72% in the prediction of a PTH-stimulated osteoblastic activity. Several cytokines
and growth factors have been shown to exert a PTH-low bone turnover [80].
The correlation between plasma bAP and iPTH shown like action on bone cells. Among them, IL-1, IL-6, and
TNF are usually found increased in the plasma of hemo-in Figure 1 illustrates how difficult it is to separately
interpret either of the values. Only 15 to 20% of the dialysis patients [37, 83]. Fourth, the serum concentration
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of certain electrolytes could influence the concentration bone resorption appears to predominate over bone for-
mation, as evidenced by the bone loss observed duringof bAP. It has been demonstrated that bAP activity is
proportional to the concentration of phosphate in the the first year following a kidney graft. Unfortunately,
our understanding of bone metabolism during kidneyculture milieu [84]. The release of bAP activity into the
circulation can be negatively regulated by calcium [51]. transplantation is limited, as few studies with bone histo-
morphometrical data have been performed so far.Likewise, an inverse relationship between plasma urea
concentration and bAP activity has been observed in the In most cases, the response to medical treatment in
uremic patients with secondary hyperparathyroidismrat [85]. Finally, the association of high bAP with low
iPTH levels might surprisingly indicate the sign of a such as oral or intravenous calcitriol has been based on
the diminution of plasma iPTH levels alone. However,certain degree of skeletal aluminum overload [86].
The finding of low plasma bAP concentrations with it has been noted that calcitriol can have a direct effect on
bone turnover independent of its effect on PTH synthesisiPTH levels higher than 200 pg/ml in 15 to 20% of hemo-
dialysis patients may have several explanations. First, [68]. Calcitriol decreases the expression of PTH recep-
tors on osteoblasts and, thereby, the action of PTH onthis strongly suggests that an increased plasma iPTH is
not always indicative of high bone turnover in these bone remodeling. Such an effect could lead to the initia-
tion of a low bone turnover bone disease even in thepatients. Second, a low plasma bAP level probably re-
flects reduced bAP synthesis by uremic osteoblasts. It has presence of relatively high plasma iPTH levels [9, 68,
91]. We have observed that plasma bAP levels can helpbeen shown that cultured osteoblasts from hemodialysis
patients respond less well to several stimuli, including in making a decision to lower the dose or to stop calcitriol
altogether [68].PTH, than those from normal individuals [87]. Third,
the poor response of osteoblasts to PTH and the low In summary, all of the observations described earlier in
this review suggest that in the absence of bone histology,plasma bAP may result from down-regulation of PTH
receptors in these uremic cells [28]. Fourth, the presence plasma bAP alone provides useful information about the
of a genetic alkaline hypophosphatasemia could be re- rate of bone remodeling in hemodialysis patients. Its
sponsible of the low plasma bAP levels as well [82, 88]. combination with plasma iPTH improves the sensitivity,
Finally, there is the possibility that no direct correlation the specificity, and the predictive value in the diagnosis
exists between plasma bAP and iPTH on the ground of the type of bone turnover. When there is a dissociation
that immunoassays overestimate the concentration of between both parameters, the sensitivity of bAP is higher
the active form of iPTH. It has recently been demon- than that of iPTH, and it is, therefore, a better indicator
strated that a non-(1-84) molecule of PTH that accumu- of bone remodeling. Nevertheless, thus far, bone histo-
lates in the serum of uremic patients can interfere with morphometry appears to be still indispensable in making
the measurement of iPTH by currently used methods the distinction between patients with normal bone and
[31, 32, 89]. patients with adynamic bone disease and in situations in
We cannot exclude that the dissociation between bAP which there is a discordance between plasma bAP and
and iPTH could also reflect an uncoupling between bone iPTH values. Again, it should be stressed that an inde-
formation and bone resorption. In this regard, on the pendent augmentation of either plasma iPTH or bAP
basis of bone histomorphometry, some patients have no may not always correspond to an increased bone turn-
tetracycline double-labeled bone formation surfaces and over.
maintained bone resorption (unpublished personal re- The idea that in hemodialysis patients one must try
sults). to maintain plasma iPTH levels three to four times higher
After surgical parathyroidectomy (PTX), the plasma than the normal values should not be taken as a general
bAP concentration behaves like iPTH, decreasing from rule, with each patient requiring an individual evalua-
an approximate mean value of 40 ng/ml before PTX to tion. As described before, paradoxically, histomorpho-
10 ng/ml three months after PTX. The coexistence of metric signs of high bone remodeling can be seen in
another high turnover bone disease should be suspected patients with normal or low plasma iPTH and vice versa.
if plasma bAP levels persist elevated after successful
PTX, as evidenced by the decrease in iPTH [90]. After
OSTEOCALCIN OR GLA PROTEINsuccessful kidney transplantation, hypocalcemia, hyper-
Osteocalcin or GLA protein (protein containing g car-phosphatemia, and calcitriol deficiency are often cor-
boxyglutamic acid) is the most abundant noncollagenicrected, and plasma iPTH returns to normal values in 70
protein of the bone matrix [92–94]. g Carboxylation oc-to 90% of patients. Plasma OC levels decrease with the
curs principally at glutamine residues 17, 21, and 24 andnormalization of renal function. Paradoxically, plasma
depends on the presence of the cofactor vitamin K. Car-bAP levels show a tendency to increase, probably be-
boxylation of the glutamic acid at position 17 seems tocause of the augmentation of bone turnover induced by
most of the immunosuppressive drugs [14, 71]. However, be essential for the structural and spatial conformation
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of the molecule allowing the interaction with hydroxyap- osteocalcin might actually be an inhibitor of bone forma-
tion. The synthesis of osteocalcin by mature osteoblasticatite crystals [95, 96]. When there is a deficiency in vita-
min Ks (K1 or phylloquinone and K2 or menaquinones: cells is probably one of the signals used by PTH to slow
osteoblastic activity and thereby bone formation [105–MK-4, MK-7, and MK-8), the carboxylate fraction of
OC tends to decrease and can be associated with a re- 108].
Numerous studies have shown the degree of interestduced bone mass and a high risk of fractures (abstract;
Nakazawa et al, Nephrol Dial Transplant 13:A43, 1998) in the use of plasma osteocalcin measurements in several
metabolic bone diseases [61, 109–112]. It has always been[97–100]. Indeed, intestinal absorption of vitamin K is
in part regulated by apolipoprotein E (apoE). Recently, considered to be a useful marker of the rate of bone
formation. However, its use in the context of renal osteo-an association has been demonstrated between the level
of plasma vitamin K and bone density, and the risk of dystrophy is still hampered by several problems. First,
many osteocalcin fragments of yet unknown function arefractures in hemodialysis patients and in postmenopausal
women having the polymorphism E4 in the apoE gene retained in the plasma of uremic patients. Second, at
least three forms of intact osteocalcin can be measured[96, 100, 101]. In addition, another recent study has sug-
gested the possibility that a deficiency in the menaqui- in the plasma: total, carboxylated, and decarboxylated.
Third, the intact molecule is rapidly degraded at roomnone MK-7 could be one of the risk factors predisposing
to adynamic bone disease in hemodialysis patients (ab- temperature. Thus, the concentration measured depends
on the characteristics of the antibodies used in the assay.stract; ibid). The physiological explanation of this is
probably that the incorporation of vitamin K-charged Many of these antibodies recognize the intact molecule
but also some of the fragments. As already mentioned,lipoproteins into intestinal, hepatic, and bone cells de-
pends exclusively on the attachment of apoE to its spe- osteocalcin fragments are also liberated during bone ma-
trix degradation. It is possible that in the future therecific receptor. In the presence of the apoE4 phenotype,
the incorporation of vitamin K seems to be reduced could be one or more of these fragments measurable
in the plasma that is specific for bone resorption [98,[100].
Human osteocalcin possesses 49 amino acids and is 113–115]. Finally, perhaps because of the limitations pre-
viously described, there is a great intra-analysis variabil-produced by only osteoblasts and odontoblasts under
the control of 1,25-OH2D3. Incidentally, it was on the ity in the dosage of OC with most of the current assays
[15, 92, 19–115].osteocalcin gene in which the sequence of DNA sensitive
to the vitamin D–vitamin D receptor complex (VDR In patients with chronic renal failure, circulating intact
osteocalcin represents 26% of total osteocalcin. The re-response element) was identified for the first time. It was
also demonstrated that the regulation of the osteocalcin maining 74% comprises mainly four fragments: N-ter-
minal, midregion, midregion C-terminal, and C-terminalgene by vitamin D was species specific. Vitamin D in-
creased its expression in humans and rats, whereas the [116, 117]. A recent study compared the measurement
of osteocalcin using six different assays: ELSA-OST-opposite effect was observed in mice [102]. Osteocalcin
and fragments of the peptide are released from bone NAT IRMA (Cis Bio Int.), ELSA-OSTEO IRMA (Cis
Bio Int.), Osteocalcin IRMA (Nichols Institute, San Juanmatrix during bone resorption. Moreover, the intact mol-
ecule can be cleaved by cathepsins and plasmin [103]. Capistrano, CA, USA), OSTK-PR RIA (Cis Bio Int.),
OSCA Test Osteocalcin RIA (Henning), and Osteocal-Plasmin cleaves it at position 43-44, giving rise to an
N-terminal [1–43] and a C-terminal [44–49] fragments cin RIA (Nichols). The authors concluded that there was
a good correlation of Osteocalcin values obtained with[104]. The C-terminal peptapeptide seems to be an im-
portant chemotactic bone factor because bone particles these kits when they examined normal individuals, pre-
menopausal, and osteoporotic women. In contrast, therelacking it become resistant to resorption [104]. Likewise,
the extracellular calcium concentration regulates the was no correlation when uremic patients and patients
with Paget’s disease were studied [118].cleavage of osteocalcin by plasmin probably through the
induction of conformational changes [104]. The half-life Using the ELSA-OSTEO IRMA kit (Cis Bio Int.),
which uses two antibodies, one recognizing the endof intact osteocalcin in the circulation is approximately
five minutes [95]. N-terminal fragment and the other recognizing a midre-
gion amino acid sequence, we and others have shownThe physiological role of osteocalcin is still not com-
pletely understood. Osteocalcin surely plays an impor- osteocalcin values four to six Z-scores higher in hemodi-
alysis patients than in normal individuals [15, 61, 119,tant role in bone formation, perhaps favoring or pre-
venting it. It was generally thought that osteocalcin 120]. In spite of this accumulation, the plasma osteocalcin
concentration demonstrated good sensitivity in makingstimulates bone formation, although recent studies have
shown an impressive augmentation of bone formation the distinction between patients with hyperparathyroid-
ism and those with normal or low bone turnover. Theand bone density in transgenic animals lacking its gene.
This has therefore led to the provoking hypothesis that values were 555 versus 198 ng/ml, respectively (Table 3)
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Fig. 2. Schematic representation of a type I
procollagen molecule. It illustrates the regions
recognized by the antibodies used to measure
the C-terminal end of type I procollagen
(PICP) and the C-terminal type I procollagen
telopeptide (ICTP).
[119]. As with other biochemical markers, diagnostic sen- closure, and oxidation of one hydrolysine and two hydro-
lysine-derived aldehyde molecules, and DPD [lysylpyri-sitivity was low when the aim was to differentiate patients
with adynamic bone disease from those with normal dinium (LP)] is formed from one lysine and two hydroly-
sine-derived aldehydes (Fig. 3) [124, 129, 130]. To date,bone turnover [15, 61]. Although weaker than bAP and
iPTH, the correlations of plasma osteocalcin with bone only these two main collagen intermolecular cross-link
molecules have been thoroughly studied; however, an-histomorphometric parameters in hemodialysis patients
were quite good [27, 29, 119]. other kind of intramolecular cross-link, which is formed
from the condensation of two aldehyde groups andThe results of these studies demonstrate the limitation
of the use of plasma osteocalcin as a biochemical marker serves to joint the a1 chains of the same collagen mole-
cule, has also been described [123–132].of bone remodeling in patients with impaired renal func-
tion and in patients under hemodialysis treatment. Obvi- Both PYD and DPD are present in bone and cartilage,
although most of the pyridinium cross-links found in theously, a clear understanding of the physiological role of
cartilage are in the form of PYD, in contrast with DPD,osteocalcin and its fragments is still lacking. The develop-
which is predominantly in bone [123, 124, 133]. Metaboli-ment of new assays will certainly increase its sensitivity
cally, these molecules are nonreducible and cannot bein the evaluation of renal osteodystrophy [121, 122].
reused during new collagen synthesis (abstract; Robins
et al, J Bone Miner Res 6:C642, 1991) [134]. Furthermore,
PYRIDINOLINES diet-derived cross-link molecules are not absorbed from
Eighty-five to 90 percent of bone matrix consists of the intestine [134]. Following bone resorption and bone
type I collagen (Fig. 2) [123–125]. It is this molecule collagen degradation by specific osteoclast-related en-
that mostly provides the mechanical force of bone tissue zymes, PYD and DPD are released into the circulation,
because of its particular intramolecular and intermolecu- and because of their low molecular weight (429 to 591
lar cross-links, which are responsible for the tensile Da), they are normally excreted into the urine, as much
strength of collagen fibers [125]. Mutations in the gene as 40% in their free forms [124, 135–138]. Usually, serum
of type I collagen a1 chain have been associated with low levels of PYD and DPD are extremely low and undetect-
bone density and osteoporosis [126]. The mechanisms able in normal individuals; therefore, their measurement
leading to the formation of these cross-links are still is commonly performed in urines. The renal clearance
poorly understood, although several biochemical pro- is different for free and conjugated forms. The fractional
cesses have been described. First, lysine residues located clearance of free forms is higher than one, suggesting
at specific regions in the type I collagen a1-chain (amino tubular secretion, whereas the fractional clearance of the
acids 103 and 1043) are hydroxylated (Fig. 3) [124–128]. conjugated forms is less than one [139]. Based on these
Then, in presence of copper, the enzyme lysyloxidase properties, it has been suggested that quantitative analy-
deaminates hydroxylated lysine residues giving rise to sis of PYD and DPD in the serum as well as in the
aldehyde groups. It is thought that PYD [hydroxylysyl- urine could provide valuable information about bone
resorption rate.pyridinium (HP)] is formed from the condensation, ring
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Fig. 3. Schematic representation of two ma-
jor collagen cross-linking molecules pyridino-
line (PYD) and deoxypyridinoline (DPD).
AA means the amino acid number at which
PYD molecule attaches to amino- and car-
boxy-terminal ends of type I collagen mole-
cules.
In the last two decades, intense research has focused Fortunately, specific polyclonal and monoclonal anti-
bodies have recently been successfully developed for theon the development of methods capable of accurately
assessing urinary and plasma concentrations of PYD and direct measurement of PYD and DPD (abstract; Robins
et al, ibid) [142, 143]. The concentrations of PYD andDPD, as well those found in a diversity of tissues includ-
ing bone, cartilage, tendon, dentin, skin, cornea, and DPD measured by ELISA methods are usually 4 to 10
times lower than the value obtained by HPLC [137, 142].vessels. The first methods were based on conventional
chromatography after borohydride reduction of collagen Nevertheless, the values obtained with either method
are excellently correlated (r 5 0.85 to 0.90). In addition,cross-links, high-performance liquid chromatography
(HPLC) using aminopropyl-silica column and radioac- some authors have even reported that the measurement
of DPD by ELISA is more reliable than by HPLC [136,tivity monitoring, followed by HPLC and fluorescence
detection techniques. Last, reproducible results have 137, 142, 143]. Moreover, measurement of PYD and
DPD, released after hydrolysis of the urine sample,been obtained using reversed-phase, ion-pair quantita-
tive HPLC (abstract; Robins et al, ibid) [124, 136–141]. either by HPLC or ELISA (Table 4), has been shown
to serve as an excellent marker of bone resorption rateCertainly, HPLC-based techniques are highly quantita-
tive and reliable; however, they are too time consuming in malnourished children, osteoporotic and postmeno-
pausal women, primary and secondary hyperparathy-and cumbersome to become a routine clinical applica-
tion. roidism, rheumatoid arthritis and osteoarthritis, Paget’s
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Table 4. Measurement of pyridinolines in metabolic bone disease
Urine
Author Year Pathology DPD PYD Method
Harvey RD 1991 Hyperthyroidism ↑ ↑ HPLC
Garnero P 1994 Hyperthyroidism ↑ HPLC
Body JJ 1992 Hypercalcemia of malignancies ↑ ↑ HPLC
Bettica P 1992 Paget’s disease ↑ ↑ HPLC
Osteoporosis ↑ ↑
Branca F 1992 Malnutrition ↑ ↑ HPLC
Seibel MJ 1992 Hyperparathyroidism ↑ ↑ HPLC
Uebelhart D 1991 Menopausal women ↑ ↑ HPLC
Hormonal treatment ↓ ↓
Delmas P 1991 Osteoporosis ↑ ↑ HPLC
Seibel MJ 1989 Arthritis ↑ ↑ HPLC
Seibel MJ 1994 Vertebral osteoporosis ↑ ↑ HPLC and ELISA





Hodsman AB 1993 Osteoporosis ↑ HPLC and ELISA
Kamel S 1995 Vitamin D deficiency ↑ ↑ HPLC and ELISA
Seyedin S 1993 Osteoporosis ↑ HPLC and ELISA
Renal insufficiency 5 5
Delmas P 1993 Paget’s disease ↑ ELISA
Ezzat S 1993 Acromegalia ↑ ↑ ELISAa
Eastell R 1997 Osteoporosis ↑ ↑ HPLC
Serum
DPD PYD
Uren˜a P 1995 Hemodialysis ↑ ELISA
Vaccaro F 1996 Renal transplantation ↑ ↑ ELISA
Ibrahim S 1995 Peritoneal dialysis ↑ ↑ HPLC and ELISA
Coen G 1998 Hemodialysis ↑ RIA
Abbreviations and symbols are: DPD, deoxypyridinoline; PYD, pyridinoline; HPLC, high performance liquid chromatography; ELISA, enzyme-linked immunosor-
bent assay; RIA, radioimmunoassay; 5, non:modified; ↑, increased; ↓, decreased.
a Antibodies against crosslink type-I collagen telopeptide
disease, acromegaly, hyperthyroidism, in patients with min) or were undergoing dialysis therapy. As expected,
serum levels of PYD and DPD increased in patients withtumor-associated hypercalcemia, and in uremic patients
(Table 4; abstract; Robins et al, ibid) [93, 119, 134–137, severe renal failure. In a study dealing with patients
treated by hemodialysis and peritoneal dialysis, the au-140–150]. In addition, an Italian group has recently dem-
onstrated the increase in urinary excretion of PYD and thors observed that circulating PYD and DPD levels
were 50 to 100 times higher than in controls, decreasedDPD in normocalcemic patients with kidney transplanta-
tion was more sensitive than plasma measurement of postdialysis, and could be measured in the dialysate
[149].iPTH, bAP, and tAP for the diagnosis of secondary hy-
perparathyroidism [150]. In another study dealing with Recently, using a competitive enzyme immunoassay
for the measurement of PYD in the serum (Metra Bio-patients treated by peritoneal dialysis, PYD and DPD
concentrations in serum, urine, and dialysis fluid were systems), it has been found that serum levels of PYD
were significantly increased in osteoporotic women, pa-well correlated with plasma iPTH and bAP levels. More-
over, the authors observed that circulating PYD and tients with hyperthyroidism, and patients with primary
hyperparathyroidism [152]. With this ELISA, we as-DPD levels progressively increased with the duration of
renal failure and with the time spent on peritoneal dial- sessed serum-free PYD levels in a group of 37 uremic
patients undergoing hemodialysis. We found that theseysis [149].
Few studies have been performed concerning the me- patients had markedly increased (10- to 30-fold) serum
PYD levels compared with normal individuals (Table 3)tabolism of PYD and DPD in uremic patients with or
without bone diseases. Two recent observations have [119]. High serum PYD levels were generally associated
with high turnover bone disease and were positively cor-suggested that urinary cross-link excretion was unaf-
fected by renal dysfunction [142, 151]. However, none related with bone resorption and bone formation param-
eters. These correlations were comparable to thoseof the patients included in these two studies had ad-
vanced renal failure (creatinine clearance below 10 ml/ found between serum bAP and bone histomorphometric
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parameters. However, serum PYD was correlated sig- However, few studies have been performed in uremic
patients. A decade ago, a correlation between serumnificantly better with bone histology than either serum
iPTH or osteocalcin [119]. No difference was observed TRAP and bAP levels was demonstrated using electro-
phoretic methods [155]. Another group, using an enzy-in serum PYD levels between patients dialyzed on high-
flux or standard cellulosic dialysis membrane, which may matic method, has recently shown a correlation between
serum TRAP activity and the number of osteoclasts andindicate that the type of dialysis membrane would not
have a major influence on serum PYD levels. In a recent the percentage of eroded bone surface (abstract; Mal-
luche et al, J Am Soc Nephrol 2:337, 1991). Similarly,study, using a commercial radioimmunoassay from Nich-
ols, it has been observed that serum DPD levels higher serum TRAP appears to correlate with plasma tAP and
iPTH [164–167].than 21 nmol/liter had a sensitivity of 88% and a spec-
ificity of 93% in the diagnosis of a high remodeling Specific antibodies against TRAP have been success-
fully developed and applied in an ELISA [154, 168].disease [81].
From these studies, it can be argued that serum PYD With this method, elevated levels of TRAP have been
found in the serum of patients with primary hyperpara-and DPD may be useful biochemical markers of bone
resorption in chronic renal patients. It seems that the thyroidism. Surprisingly, however, it was found that nor-
mal subjects had measurable amounts of serum TRAPsensitivity and specificity of these markers are greater
in cases of increased bone remodeling. Hopefully, more [154]. It is likely, therefore, that the specificity of this
ELISA assay may not be perfect, in that it might besensible measurements of collagen cross-linked mole-
cules will be developed and will become common tests recognizing other acid phosphatases or the same TRAP
produced by other cells. Significant TRAP activity hasin clinical practice.
recently been detected in osteoblasts and osteocytes
[154].
TARTRATE-RESISTANT ACID PHOSPHATASES
To date, the value of serum TRAP measurement in
Acid phosphatases are lysosomal enzymes produced uremic hemodialysis patients still remains to be estab-
by osteoclasts, prostate, uterus, pancreas, spleen, blood lished. The sensitivity of enzymatic methods and the few
red and white cells, and platelets. Analogous to tAPs, available immunological assays are still low. Certainly,
the different acid phosphatases can be identified and progress in understanding its physiological role as well
measured by enzymatic, electrophoretical, or chromato- as its biochemistry and immunochemistry should lead to
graphic methods [152–155]. Thus, the bone-specific acid the development of more sensitive assays [168].
phosphatase (TRAP), or the purple acid phosphatase
because of its iron content, has been proposed as a poten-
PROCOLLAGEN TYPE I CARBOXY-TERMINALtial marker of bone resorption. TRAP has a molecular
EXTENSION PEPTIDEweight of 30 kDa but circulates in the serum as a 250
kDa complex, which also contains calcium [152]. Serum Type I procollagen carboxy-terminal extension pep-
tide (PICP) results from the extracellular cleavage of aTRAP had previously been determined by virtue of its
resistance to tartric acid. However, many questions have molecule of type I procollagen at the moment of its
incorporation into the bone matrix (Fig. 2) [169, 170].been raised about its osteoclast specificity. Moreover,
even though TRAP appears to be essential to the process PICP has a molecular weight of approximately 100,000
Da. Its plasma concentration is not altered by renal fail-of bone resorption, its physiological role on the skeleton
is yet ill understood. It is known that TRAP dephosphor- ure because its degradation takes place in the liver
through the mannose-6-phosphate receptor. Specific an-ylates a variety of bone matrix proteins such as osteopon-
tin and sialoprotein [156]. In addition, transgenic mice tibodies against PICP have been developed and are actu-
ally employed to measure its plasma concentration [119,with targeted disruption of the TRAP gene develop an
osteopetrotic phenotype with altered osteoclastic func- 169–176]. Because PICP is produced by osteoblasts dur-
ing the process of bone formation, plasma PICP concen-tion [157]. In spite of these transgenic studies, little is
known about the TRAP gene [158, 159]. It belongs to a tration has been proposed as a biochemical marker of
bone formation.family of genes that codes for iron transport proteins in
the placenta. Accordingly, the TRAP gene seems to be Nondialyzed patients with chronic renal failure have
significantly increased plasma PICP levels [171]. How-regulated at the transcriptional level by extracellular iron
concentrations. It possesses an iron-sensitive DNA se- ever, this increase does not correlate with other humoral
markers of bone turnover or with bone histomorphome-quence (iron-response element) on its 59 untranslated
region [160]. trical parameters. In the same study, it was observed that
patients receiving 1,25OH2D3 had higher plasma PICPIn some studies, the amount and the activity of TRAP
seems to correlate with bone resorption rate (abstract; levels than patients without treatment. In patients al-
ready treated by hemodialysis, the results are contradic-Lam et al, Clin Chem 30:457, 1984) [152, 154, 161–163].
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tory. Some workers have found that plasma PICP con- loid deposits in osteoarticular tissues [183]. In addition
centration provides useful information regarding the to being an indicator of an inflammatory state, it has
degree of bone formation. They also observed that PICP been suggested that b2m could serve as a bone remodel-
levels correlate quite well with plasma bAP, osteocalcin, ing marker as well [184]. Serum b2m concentrations have
iPTH, and bone formation rate (BFR) [169]. been found to correlate with serum TRAP in postmeno-
By analogy with plasma bAP, PICP levels increased pausal women [185, 186]. Moreover, in a recent study,
significantly during the first two weeks after surgical we have observed that patients with severe secondary
PTX, probably as a consequence of diminished osteoclast hyperparathyroidism showed significantly higher serum
activity following the reduction of iPTH levels and an b2m levels than patients with normal bone turnover. In
increase in mineral deposition [119, 173, 177]. However, addition, serum b2m correlated with serum bAP, PYD,
our own observations have not demonstrated any great and osteocalcin levels [183].
value of plasma PICP in the diagnosis of the type of Regarding AGEs, these also have a tendency to accu-
bone remodeling in hemodialysis patients [29, 119, 170, mulate in the serum of uremic patients. Recent studies
177]. Additional studies remain to be performed in order have shown that AGEs were able to stimulate bone
to define its value in renal osteodystrophy.
resorption probably through the stimulation of IL-6 pro-
duction [35, 187]. Because IL-6 is one important media-
PROCOLLAGEN TYPE I CROSS-LINKED tor of the action of PTH on bone cells [188], it is possible
CARBOXY-TERMINAL TELOPEPTIDE that AGEs could influence bone metabolism in hemodi-
Telopeptides are small amino acid sequences originat- alysis patients. Finally, bone sialoprotein, a glycoprotein
ing from the nonhelical ends of collagen molecules. For of the bone matrix with a molecular weight of 70 to 80
instance, procollagen type I cross-linked carboxy-termi- kDa, has been shown to be a bone indicator of bone
nal telopeptide (ICTP) is a part of type I collagen resorption in cancer patients and in menopausal women
released during bone resorption and containing cross- [189].
linking molecules (Fig. 2). One molecule of ICTP is com-
posed of two C-terminal fragments from the a1 chain of
CONCLUSIONStype I collagen, one helical segment from the a1 or a2
chain of collagen, and a cross-linker (PYD or DPD). Its In the absence of bone biopsy information, it seems
molecular weight is approximately 9,000 Da [178]. ICTP that there is no ideal marker of bone remodeling in
is released into the circulation after the degradation of uremic patients. The time has come to regard the plasma
several mature collagen molecules of the bone matrix iPTH concentration as the marker of parathyroid activity
[125, 169, 170]. Therefore, plasma ICTP levels should and not as the indicator of bone turnover. As mentioned
reflect the degree of bone resorption.
before, increased plasma iPTH levels are not alwaysThese assays of plasma ICTP use polyclonal antibodies
synonymous with high turnover bone disease and viceagainst a small group of cross-linked peptides of the
versa. Among the biochemical markers of bone remodel-human type I collagen [179] or against a group of eight
ing revised herein, plasma bAP concentration appears toamino acids (EKAHDGGR) that correspond to the
be more sensitive than iPTH, osteocalcin, TRAP, PYD,C-telopeptide domain of the a1 chain of type I collagen
PICP, and ICTP in distinguishing the type of bone dis-[180]. Several observations have demonstrated a good
ease and, in particular, estimating the BFR. It is not yetcorrelation between plasma ICTP and histomorphome-
clear whether it can separate patients with adynamictric parameters of bone resorption in patients with a
bone disease from those with normal bone remodeling.diversity of metabolic bone diseases [178, 181]. However,
Renal osteodystrophy has been considered for a longother clinical studies have not supported this method as
a specific indicator of bone resorption rate [145]. In the time as a disease in which coupling between resorption
case of patients with chronic renal failure, ICTP tends and formation was thought tight. It now becomes clear
to accumulate in the serum with the decline in renal that other factors besides PTH can influence bone turn-
function and even further in hemodialysis patients. The over and induce a decoupling between resorption and
few studies performed in hemodialysis patients have not formation. A specific marker of bone resorption would
supported its use as a humoral marker of bone remodel- therefore be suitable. Serum DPD appears to fill such a
ing [119, 145, 182]. requirement. However, further developments are neces-
sary to improve its sensitivity and accuracy. The future
b2-MICROGLOBULIN, ADVANCED generalized use of these markers, individually or in com-
END-GLYCATION PRODUCTS, AND bination with other methods, will undoubtedly improve
BONE SIALOPROTEIN the diagnosis and the treatment of renal osteodystrophy.
Further studies, based on bone histomorphometry, areb-2 Microglobulin (b2m) accumulates in the serum of
chronic renal patients and can lead to b2m-related amy- clearly needed to better understand the value of these
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